Lonza has plans to invest 219 million dollars to construct a new manufacturing complex in Visp, Switzerland. The 2,000 sq m project will comprise a customer dedicated manufacturing line for antibody-drug conjugate payload molecules and will also prove useful for accommodating future small molecule expansions.
Read on